Deferoxamine Mesylate in patients with intracerebral haemorrhage: a Multi-Center, Randomised, Double-Blind, Placebo-Controlled, Phase II Trial

BACKGROUND: Iron, from hemolyzed blood, is implicated in secondary injury after intracerebral haemorrhage (ICH). We aimed to evaluate the safety of the iron chelator, Deferoxamine Mesylate (DFO), and whether it merits investigation in a Phase-III study to definitively assess its effectiveness in imp...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Lancet Neurol
मुख्य लेखकों: Selim, Magdy, Foster, Lydia D, Moy, Claudia S, Xi, Guohua, Hill, Michael D, Morgenstern, Lewis B, Greenberg, Steven M, James, Michael L, Singh, Vineeta, Clark, Wayne M, Norton, Casey, Palesch, Yuko Y, Yeatts, Sharon D
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494117/
https://ncbi.nlm.nih.gov/pubmed/30898550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(19)30069-9
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन